CrossrefInfokarte
PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer
European Journal of Cancer · 2026-12 · 249 · 117816
DOI: 10.1016/j.ejca.2026.117816 ↗Abstract
Kein Abstract verfügbar.
EUVIMED